Home Stock Ideas Long Ideas Healthcare  Summary Immunic, Inc. (IMUX) is rated Hold due to high cash burn, heavy dilution, and reliance on a single near-term catalyst. Vidofludimus calcium (IMU-838) Phase 3 MS trial results, expected late 2026, are pivotal for IMUX's future revenue and valuation. Recent $187M private placement and $200M in warrants extend IMUX's cash runway to Phase 3 readout, and hopefully to the drugs rollout to the market, reducing near-term dilution risk. If Vidofludimus calcium fails, IMUX faces severe downside as backup assets are 6–10 years from market, risking insolvency. LPETTET/E+ via Getty Images Immunic, Inc. ( IMUX ) is a pre-revenue company listed on the NASDAQ, in the stage of clinical drug development, which means that they are burning millions of dollars for R&D (research and development) of new therapeutic assets.…